Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

  • There is currently no data for INDV

Director/PDMR Shareholding

16 Mar 2022 13:04

RNS Number : 0037F
Indivior PLC
16 March 2022
 

INDIVIOR PLC (THE 'COMPANY')

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ('PDMR') AND PERSONS CLOSELY ASSOCIATED WITH THEM

The Company announces that on March 15, 2022, Conditional Awards ('Awards') over Ordinary Shares of $0.10 each ('Shares') were granted to the Executive Directors set out below under the Indivior Deferred Bonus Plan 2018 (the 'DBP').

Awards granted under the DBP represent the deferral of 25% of the gross bonus earned under the Indivior 2021 Annual Incentive Plan. The Awards will normally vest on the second anniversary of the Award date and are subject to continued employment. No consideration is payable either on the grant or vesting of the Awards.

Name

Number of Shares under Award

Executive Directors

Mark Crossley

96,077

Ryan Preblick

35,703

 

This notification is made in accordance with the requirements of the UK Market Abuse Regulation.

Kathryn Hudson

Company Secretary

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Mark Crossley

2

 

Reason for the notification

 

a)

 

Position/status

  

Director / PDMR - Chief Executive Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

Indivior PLC

b)

 

LEI

213800V3NCQTY7IED471

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of US$0.10

 

 

GB00BRS65X63

b)

 

Nature of the transaction

Award over Ordinary Shares

 

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

Volume(s)

N/A

96,077

d)

 

Aggregated information

 

- Aggregated volume

- Price

 

 

N/A

e)

 

Date of the transaction

March 15, 2022

f)

 

Place of the transaction

 

Outside a trading venue

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Ryan Preblick

2

 

Reason for the notification

 

a)

 

Position/status

  

Director / PDMR - Chief Financial Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

Indivior PLC

b)

 

LEI

213800V3NCQTY7IED471

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of US$0.10

 

 

GB00BRS65X63

b)

 

Nature of the transaction

Award over Ordinary Shares

 

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

Volume(s)

N/A

35,703

d)

 

Aggregated information

 

- Aggregated volume

- Price

 

 

N/A

e)

 

Date of the transaction

March 15, 2022

f)

 

Place of the transaction

 

Outside a trading venue

 

Indivior PLC's Legal Entity Identifier code is 213800V3NCQTY7IED471.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGPUGUWUPPGWQ
Date   Source Headline
28th Feb 20259:43 amRNSDirector/PDMR Shareholding
28th Feb 20259:42 amRNSDirector/PDMR Shareholding
28th Feb 20257:00 amRNSHolding(s) in Company
27th Feb 20254:31 pmRNSDirector/PDMR Shareholding
27th Feb 20254:29 pmRNSDirector/PDMR Shareholding
27th Feb 20257:00 amRNSJoseph Ciaffoni Appointed Chief Executive Officer
25th Feb 20257:00 amRNSHolding(s) in Company
24th Feb 20257:00 amRNSFDA Approval of SUBLOCADE Label Changes
20th Feb 20257:00 amRNSFinal Results
12th Feb 20257:00 amRNSDelayed FDA Approval of SUBLOCADE Label Changes
4th Feb 20253:12 pmRNSNotice of Results
4th Feb 20257:00 amRNSCompletion of Share Repurchase Program
4th Feb 20257:00 amRNSTransaction in Own Shares
3rd Feb 20259:26 amRNSTotal Voting Rights
3rd Feb 20257:00 amRNSAppointment of Independent Non-Executive Director
28th Jan 20253:30 pmRNSDr. David Wheadon appointed Chair of the Board
28th Jan 20259:43 amRNSHolding(s) in Company
28th Jan 20257:00 amRNSTransaction in Own Shares
27th Jan 20259:08 amRNSHolding(s) in Company
21st Jan 20257:00 amRNSTransaction in Own Shares
16th Jan 20254:00 pmRNSReplacement Transaction in Own Shares
14th Jan 20257:00 amRNSTransaction in Own Shares
9th Jan 20251:00 pmRNSIndivior Provides Historical Financials in US GAAP
7th Jan 20258:55 amRNSHolding(s) in Company
7th Jan 20257:00 amRNSTransaction in Own Shares
2nd Jan 20259:31 amRNSTotal Voting Rights
31st Dec 20249:53 amRNSHolding(s) in Company
31st Dec 20247:00 amRNSTransaction in Own Shares
24th Dec 20247:00 amRNSTransaction in Own Shares
23rd Dec 202410:32 amRNSDirector/PDMR Shareholding
17th Dec 20247:00 amRNSIndivior Announces Changes to Board of Directors
17th Dec 20247:00 amRNSTransaction in Own Shares
10th Dec 20247:00 amRNSTransaction in Own Shares
3rd Dec 20247:00 amRNSTransaction in Own Shares
2nd Dec 20249:44 amRNSTotal Voting Rights
26th Nov 20247:00 amRNSTransaction in Own Shares
22nd Nov 20247:00 amRNSIndivior to Participate in Upcoming Investor Event
19th Nov 20247:00 amRNSTransaction in Own Shares
18th Nov 20248:48 amRNSHolding(s) in Company
15th Nov 20247:00 amRNSDirector Declaration
12th Nov 20247:00 amRNSTransaction in Own Shares
11th Nov 20242:29 pmRNSHolding(s) in Company
8th Nov 20244:50 pmRNSBlock listing Interim Review
8th Nov 20247:00 amRNSIndivior Responds to Letter from Oaktree
5th Nov 20247:00 amRNSIndivior Completes Refinance of Secured Term Loan
5th Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 202411:59 amRNSTotal Voting Rights
29th Oct 20247:00 amRNSTransaction in Own Shares
24th Oct 20247:00 amRNS3rd Quarter Results
22nd Oct 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.